Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last ¥1,981 JPY
Change Today +1.00 / 0.05%
Volume 38.5K
As of 2:00 AM 10/7/15 All times are local (Market data is delayed by at least 15 minutes).

fuji pharma co ltd (4554) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/19/15 - ¥2,700
52 Week Low
10/16/14 - ¥1,889
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for FUJI PHARMA CO LTD (4554)

Related News

No related news articles were found.

fuji pharma co ltd (4554) Related Businessweek News

No Related Businessweek News Found

fuji pharma co ltd (4554) Details

Fuji Pharma Co., Ltd. develops, manufactures, and markets pharmaceutical products in Japan and internationally. It offers injection agents, internal drugs, drugs for external use, and diagnostic products. The company’s products and services include medical care for women; in vitro diagnostics, acute medical care products, and curative medicines; and information regarding pharmaceuticals and health. Fuji Pharma Co., Ltd. was founded in 1965 and is headquartered in Tokyo, Japan.

1,467 Employees
Last Reported Date: 12/19/14
Founded in 1965

fuji pharma co ltd (4554) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

fuji pharma co ltd (4554) Key Developments

Guerbet Signs an Agreement with Fuji Pharma to Market its Range of Contrast Media in Japan

Guerbet announced an agreement with Fuji Pharma Co., Ltd. to distribute and promote its range of contrast media for MRI, X-Ray imaging and interventional radiology in Japan to be effective on October 2nd 2015. This offering in Japan includes three contrast media. One for MRI imaging: Magnescope (Registered) (distributed outside of Japan under the brand name Dotarem (Registered), leading contrast agent in Europe), one for X-Ray imaging contrast media: Hexabrix(Registered) 320, one for interventional radiology: Lipiodol (Registered).

Fuji Pharma Co., Ltd. to Report Q3, 2015 Results on Aug 07, 2015

Fuji Pharma Co., Ltd. announced that they will report Q3, 2015 results on Aug 07, 2015

Fuji Pharma Co., Ltd., Q2 2015 Earnings Call, May 15, 2015

Fuji Pharma Co., Ltd., Q2 2015 Earnings Call, May 15, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4554:JP ¥1,981.00 JPY +1.00

4554 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4554.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4554 Industry Range
Price/Earnings 15.2x
Price/Sales 1.0x
Price/Book 1.1x
Price/Cash Flow 11.6x
TEV/Sales 0.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FUJI PHARMA CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at